Novartis posts strong third quarter results and raises guidance

18 October 2018
novartis-big

Swiss giant Novartis (NOVN: VX) has released an upbeat financial results statement for the third quarter of 2018, with a 3% rise in revenues to $12.8 billion, roughly in line with analysts’ expectations.

Following Generally Accepted Accounting Principles (GAAP), the earnings per share figure came in at $0.70, based on net income of $1.6 billion.

The firm raised its full year guidance, stating it now expects sales to grow in the mid-single-digit percentage range, with operating profit also higher, in the mid-to-high-single-digit percentage range.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical